Cover Image

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy

Background: Treatment of ovarian clear cell carcinoma (CCC) poses many challenges. Effective treatment options for recurrent and metastatic disease remain limited. Case: A 70-year-old woman with recurrent metastatic ovarian CCC experienced durable response to the combination of pembrolizumab, a PD-1...

Full description

Saved in:

Bibliographic Details
Main Authors:	Blair McNamara (Author), Stefania Bellone (Author), Cem Demirkiran (Author), Tobias Max Philipp Hartwich (Author), Alessandro D. Santin (Author)
Format:	Book
Published:	Elsevier, 2023-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
by: Blair McNamara, et al.
Published: (2023)

Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer
by: Michelle Greenman, et al.
Published: (2024)

Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series
by: Corinne A. Calo, et al.
Published: (2023)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
by: Jonathan T. Hunt, et al.
Published: (2021)

Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer
by: Yutaka Yoneoka, et al.
Published: (2024)

Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas
by: Michelle Greenman, et al.
Published: (2024)

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
by: Chanhee Han, et al.
Published: (2018)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
by: Kaito Mimura, et al.
Published: (2022)

A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
by: Naaman Mehta, et al.
Published: (2023)

Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series
by: Shannon M. Glynn, et al.
Published: (2024)

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
by: Mingyang Feng, et al.
Published: (2022)

The efficacy and safety of lenvatinib plus pembrolizumab therapy in patients with uterine carcinosarcoma
by: Risako Ozawa, et al.
Published: (2024)

Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with ESR1 gene amplification
by: Jenny L. Soiffer, et al.
Published: (2024)

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
by: Zhiwei Zheng, et al.
Published: (2022)

1 Examining the immune tumor microenvironment of endometrial cancer patients treated with pembrolizumab plus lenvatinib
by: Erica V. Carballo, et al.
Published: (2023)

Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report
by: Massine Fellouah, et al.
Published: (2023)

Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
by: Sherry Shen, et al.
Published: (2021)

Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
by: Nicoletta Colombo, et al.
Published: (2023)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
by: Peter G. Rose, et al.
Published: (2023)

Radiation recall dermatitis during treatment of endometrial cancer with pembrolizumab plus lenvatinib: A case report
by: Elise Heisler, et al.
Published: (2023)

Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2024)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
by: Alessandro D. Santin, et al.
Published: (2017)

Combination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
by: A. D. Darenskaya, et al.
Published: (2024)

Ovarian clear cell carcinoma with uterine intramural recurrence: Case report of ovarian clear cell carcinoma with fertility sparing treatment
by: Ting Yu Chang, et al.
Published: (2024)

Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
by: Julie Terzic, et al.
Published: (2020)

Pattern of disease and response to pembrolizumab in recurrent cervical cancer
by: Kathryn M. Miller, et al.
Published: (2021)

A complete durable response of vaginal clear cell carcinoma with pembrolizumab: A case report
by: Hector S. Porragas-Paseiro, et al.
Published: (2023)

Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID
by: Stefania Bellone, et al.
Published: (2023)

Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
by: Yu-Chien Lin, et al.
Published: (2020)

Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: A case report
by: M. Lehmann, et al.
Published: (2023)

Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
by: Yoichi Nishii, et al.
Published: (2022)

Systemic embolic events with nonbacterial thrombotic endocarditis as manifestations of recurrent ovarian clear cell carcinoma
by: Yu-Kai Lin, et al.
Published: (2015)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
by: Qiao Liu, et al.
Published: (2022)

Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy
by: Valerie A. Allen, et al.
Published: (2016)

Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer
by: Xue Zhang, et al.
Published: (2024)

A case of complete remission of intractable gestational choriocarcinoma with subsequent chemotherapy after pembrolizumab
by: Kaoru Niimi, et al.
Published: (2023)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
by: Meiyu Wu, et al.
Published: (2022)

Effects of three flavonoids on the metabolism of lenvatinib
by: Jinzhao Yang, et al.
Published: (2024)

A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer
by: Morgan Burke, et al.
Published: (2018)